2007 Drug Topics OTC Cough, Cold, and Flu survey

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.

The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.

Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.

The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.

Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.

James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.